Loading...
By the Editors
During the past week, the FDA issued its third emergency use authorization for a COVID-19 vaccine — this time, Johnson & Johnson's single-dose, adenovirus-vectored vaccine. The CDC quickly followed suit and recommended its use in adults aged 18 and older — and then posted interim clinical considerations for the vaccine on its website.
Elsewhere, researchers reported delayed, large cutaneous reactions in 12 patients after receiving the first dose of Moderna's mRNA vaccine. The reactions were not contraindications to the second dose, and all patients completed the vaccine series.
In addition, in a randomized trial from Colombia, the antiparasitic ivermectin did not improve outcomes in patients with mild COVID-19. Whether the drug helps in COVID-19 has been a subject of much debate.
And finally, a study from Italy suggested that testing conjunctival swab specimens could be an additional diagnostic method for SARS-CoV-2 infection.
Catch up on these and all of our COVID-19 stories from the past week at the links below.
Comment
LINK(S):
COVID-19 Vaccines: J&J Clinical Considerations / Polysorbate / Post-Vaccine COVID (Mar. 4) (Free)
COVID-19: Ivermectin & Mild Illness / Seroprevalence in Children / Conjunctival Swabs? / Cardiac Screening in Pro Athletes (Mar. 4) (Free)
COVID-19: Blood Type A / Increased Transmissibility of B.1.1.7 (Mar. 3) (Free)
COVID-19 Vaccine: Delayed Large Local Reactions Possible (Mar. 3) (Free)
COVID-19: Rising Cases / Masks & Breathing in Young Children (Mar. 2) (Free)
COVID-19 Vaccines: Missing Race & Ethnicity Data / Single-Dose Effectiveness / J&J Recommendations (Mar. 2) (Free)
WHO Recommends Against Hydroxychloroquine for COVID-19 Prevention (Mar. 1) (Free)
Third COVID-19 Vaccine Authorized, Recommended in U.S. (Feb. 28) (Free)